Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02084641 · ClinicalTrials.gov registry record · NA

Adipose Tissue Response to Overfeeding in Insulin Resistance-Prone vs. Insulin Sensitive Humans

A NA study, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
58
Enrollment target

NCT02084641: Completed NA study, sponsored by Stanford University.

NCT02084641 is a NA study that has completed, run by Stanford University. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02084641, a NA study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
58 participants
Enrollment target

Study Summary

Obesity has become an epidemic worldwide. Data from our laboratory and others demonstrate that most of the excess morbidity from obesity is related to insulin resistance (IR). While total adiposity correlates with insulin resistance, not all obese individuals are IR. When obese IR individuals lose weight in response to caloric restriction, even moderate loss of body fat results in improved insulin sensitivity (IS). With massive weight loss, either dietary or surgical, even the most IR individuals can completely reverse their insulin resistance. But why is one individual IR at a BMI of 26 and another IS at a BMI of 35? There must be differences in the manner in which adipose cells/tissue respond to caloric excess and weight gain. One potentially unifying hypothesis with regard to obesity-associated insulin resistance is that those individuals who fail to respond to caloric excess/obesity with adequate adipocyte differentiation and expanded subcutaneous fat storage capacity develop increased circulating FFAs, ectopic fat deposition, stress on adipocytes, triggering localized and systemic inflammation and ultimately insulin resistance in skeletal muscle. Clearly, the best way to examine the human response to obesity is to challenge overweight individuals with the need to store excess triglyceride in adipose tissue. Specific aims are: 1. Test the hypothesis that impaired adipogenesis and fat storage capacity are associated with insulin resistance by comparing 1) cell size distribution; 2) gene markers of adipose cell differentiation; 3) differentiation of isolated preadipocytes in IR-prone vs IS individuals subjected to caloric excess. 2. Determine if circulating (daylong FFA, two-stage Insulin Suppression Test) and ectopic fat (MRI liver, CT abdomen) are worsened to a greater degree in IR-prone vs IS individuals subjected to caloric excess. 3. Determine whether differences in inflammation and/or innate or adaptive immune response are associated with insulin resistanc

Primary Outcome

this will be quantified by measuring: 1) adipose cell size distribution; 2) gene markers of adipose cell differentiation; 3) differentiation of isolated preadipocytes in IR-prone vs IS individuals subjected to caloric excess; in vivo triglyceride synthesis using stable isotope methods

Interventions

  • OTHER Over feeding

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2011-09
Est. Completion 2016-08
Phase NA
Stanford University

1,744 total trials

What the finished NCT02084641 record still lists

NCT02084641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which Over feeding is the first listed.

NCT02084641 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02084641 about?

NCT02084641 is a clinical study titled "Adipose Tissue Response to Overfeeding in Insulin Resistance-Prone vs. Insulin Sensitive Humans". Obesity has become an epidemic worldwide. Data from our laboratory and others demonstrate that most of the excess morbidity from obesity is related to insulin resistance (IR). While total adiposity correlates with insulin resistance, not all obese individuals are IR. When obese IR individuals lose w...

What is the current status of trial NCT02084641?

This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2011-09. Estimated completion is 2016-08.

What interventions are being tested in trial NCT02084641?

The interventions under investigation include: Over feeding (OTHER).

Who is sponsoring clinical trial NCT02084641?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02084641's enrollment target sits among peer trials

58 1256th of 2000 higher than 740 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03587844 · 58 participants · Phase 2

    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

  • NCT03630991 · 58 participants · Phase 1

    Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • NCT03949855 · 58 participants · Phase 2

    Belimumab With Rituximab for Primary Membranous Nephropathy

  • NCT04069273 · 58 participants · Phase 2

    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02084641, the US trial registry maintained by the National Library of Medicine. NCT02084641 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.